Cochrane · systematic review · CD008834
Antiplatelet agents for chronic kidney disease
Natale, P, Palmer, SC, Saglimbene, VM, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
Kidney and TransplantAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 2 · 28.6%Low 3 · 42.9%Moderate 2 · 28.6%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Antiplatelet agents versus control for chronic kidney disease
Population: people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Fatal or nonfatal myocardial infarction Antiplatelet agents vs control | RR 0.88 [0.79, 0.99] | 18 studies · 15289 participants | Moderate Downgraded: risk of bias |
Fatal or nonfatal stroke Antiplatelet agents vs control | RR 1.01 [0.64, 1.59] | 12 studies · 10382 participants | Very low Downgraded: risk of bias |
Death (any cause) Antiplatelet agents vs control | RR 0.94 [0.84, 1.06] | 35 studies · 18241 participants | Low Downgraded: risk of bias |
Cardiovascular death Antiplatelet agents vs control | RR 0.87 [0.65, 1.15] | 21 studies · 9606 participants | Very low Downgraded: risk of bias |
Major bleeding Antiplatelet agents vs control | RR 1.35 [1.1, 1.65] | 29 studies · 16194 participants | Moderate Downgraded: risk of bias |
Minor bleeding Antiplatelet agents vs control | RR 1.55 [1.27, 1.9] | 21 studies · 13218 participants | Low Downgraded: risk of bias |
Early access thrombosis (before 8 weeks) Antiplatelet agents vs control | RR 0.52 [0.38, 0.7] | 8 studies · 1525 participants | Low Downgraded: risk of bias |